Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer


06 Mar 2023


Cocktail & Poster Display session


Erika Porubayeva


Annals of Oncology (2023) 8 (1suppl_2): 100898-100898. 10.1016/esmoop/esmoop100898


E. Porubayeva1, L. Urusova2

Author affiliations

  • 1 General Medicine, First Moscow State Medical University named after I.M. Sechenov (Sechenov Universaty), 119991 - Moscow/RU
  • 2 Fundamental Pathology, Endocryne Research Centre, 117273 - Moscow/RU


This content is available to ESMO members and event participants.

Abstract 91P


Adrenocortical cancer (ACC) therapy is characterized by insufficient effectiveness. Currently, mitotane, an adrenolytic drug, is the only drug approved for treatment of ACC and is used in the adjuvant setting and in case of metastatic or advanced disease. However, the administration of mitotane to certain groups of patients remains controversial due to the low response rates, high toxicity and limited data on the benefit of treatment. Expression levels of the large subunit of ribonucleotide reductase M1 (RRM1), cytochrome P450 2W1 (CYP2W1) and sterol-O-acyltransferase-1 (SOAT1) are considered as potential predictors of response to mitotane therapy. The aim of this study was to estimate the immunohistochemical expression of RRM1, CYP2W1 and SOAT1 in ACC as markers of clinical outcomes and response to the therapy with mitotane.


The study included 62 patients older than 17 years of age with a diagnosis of ACC confirmed histologically and immunohistochemically. Pathomorphological examination of surgical and consultative material from patients treated between 2005 and 2020 in Endocrinology research center and other health care centers of Russia was performed. Antibodies to SF-1, Ki-67, RRM1, CYP2W1, SOAT1 were used diluted in accordance with recommendations of firms-manufacturers for immunohistochemical detection. Kaplan-Meier method was used to estimate disease-free survival (DFS) and its predictors.


Mitotane therapy was initiated in 29 patients in the postoperative period, the control group comprised 33 patients according to results of immunohistochemical examination (level of expression of Ki-67). In the control group of patients with low and moderate RRM1, CYP2W1 and SOAT1 immunoreactivity, a better DFS was observed (p=0.037, p=0.020 and p=0.001, respectively) compared to the study group at this level of marker expression. In case of high expression levels of the markers, no statistically significant differences were found.


In this study we have identified tendences in the correlation of the expression of potential prognostic markers and DFS in our sample of patients. Evaluation of RRM1, SOAT1 and CYP2W1 immunoreactivity opens new possibilities for personalized mitotane therapy in ACC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Endocrinology Research Center, Moscow, Russia.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.